Clinical Trials Logo

CMV Viremia clinical trials

View clinical trials related to CMV Viremia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04018261 Completed - CMV Viremia Clinical Trials

Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients

Start date: July 4, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor. Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days after the treatment.

NCT ID: NCT01329185 Completed - CMV Viremia Clinical Trials

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the prevention of AIDS and so along the same lines the investigators will test the hypothesis that 14 days of the anti-viral Valganciclovir (VAL) to kidney donors prior to the transplant compared to placebo will reduce EBV and CMV viremia in the 1st year posttransplant in pediatric kidney recipients.